High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study.
Lai
Raymond
R
Bartlett
Nancy L
NL
Mackey
John R
JR
Jung
Sin-Ho
SH
Johnson
Jeffrey L
JL
Cook
James R
JR
Jones
Dan
D
Cass
Carol E
CE
Young
James D
JD
Said
Jonathan
J
Cheson
Bruce
B
Hsi
Eric D
ED
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage; D033721:Equilibrative Nucleoside Transporter 1 / Q000378:metabolism*; D005260:Female; D006689:Hodgkin Disease / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D016539:Reed-Sternberg Cells / Q000378:metabolism*; D015996:Survival Rate; D017211:Treatment Failure; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D000093542:Gemcitabine
D033721:Equilibrative Nucleoside Transporter 1; D008081:Liposomes; C438649:SLC29A1 protein, human; D003841:Deoxycytidine; D014747:Vinblastine; D004317:Doxorubicin; D000077235:Vinorelbine; D000093542:Gemcitabine